A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Active, not recruiting · Phase 1, Phase 2 · NCT02979522
Conditions: Hodgkin Disease
At a glance
- Research payments reported, 2025
- $6,189
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 59
About the trial
- Sponsor
- Takeda
- Tested
- Brentuximab vedotin (drug), Doxorubicin (drug), Vinblastine (drug), Dacarbazine (drug)
- Dates
- Started 2017-09-06; completion 2029-09-24
- Results posted
- Yes
The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen, doxorubicin (Adriamycin), vinblastine, and dacarbazine, in pediatric participants with advanced stage newly diagnosed classical CD30+ Hodgkin Lymphoma (HL).
From ClinicalTrials.gov, last updated 2025-11-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $6,189 in research payments for this study in 2025 (17 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Margaret Macy, MD Pediatric Hematology & Oncology · Aurora, CO
- Robin Norris, M.D., MPH Pediatric Hematology & Oncology · Cincinnati, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.